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Abstract: Lung cancer is the leading cause of cancer-related death in the United States.
Here, we evaluated the potential clinical utility of soluble human epidermal growth factor
receptor 2 (sHER2) for the risk assessment, screening, and diagnosis of non-small cell
lung cancer (NSCLC) using an unmatched case-control study design. Serum sHER2
concentrations were measured by immunoassay in 244 primary NSCLC cases and
218 healthy controls. Wilcoxon rank-sum tests, logistic regression models, and receiver
operating characteristic plots were used to assess whether sHER2 is associated with lung
cancer. Median serum sHER2 concentrations are higher in patients with adenocarcinoma
than squamous cell carcinoma regardless of gender, and sHER2 is a weak, independent
biomarker of adenocarcinoma, but not of squamous cell carcinoma, adjusted for age and
gender. The age-adjusted relative risk (odds) of adenocarcinoma is 3.95 (95% CI: 1.22,
12.81) and 7.93 (95% CI: 2.26, 27.82) greater for women and men with high sHER2
concentrations (≥6.60 ng/mL) vs. low sHER2 concentrations (≤1.85 ng/mL), respectively.
When adjusted for each other, sHER2, age, and gender discern healthy controls from
patients with primary adenocarcinomas of the lung with 85.9% accuracy. We conclude that
even though serum sHER2 is not a strong, stand-alone discriminatory biomarker of
adenocarcinoma, sHER2 may be a useful, independent covariate in multivariate risk
assessment, screening, and diagnostic models of lung cancer.
Keywords: soluble human epidermal growth factor receptor 2 (sHER2); non-small cell
lung cancer; adenocarcinoma; squamous cell carcinoma (SCC); risk assessment; screening;
early detection; diagnosis

1. Introduction
Lung cancer is the leading cause of cancer-specific mortality for men and women in the U.S. [1–3].
The National Cancer Institute’s (NCI) Surveillance Epidemiology and End Results program estimated
that 226,160 new lung cancer cases were diagnosed in the U.S. in 2012, and that 160,340 individuals
died of this disease. Of all lung cancers, 99% consist of either small cell carcinomas (13.9%) or
non-small cell carcinomas (85.1%). Histological subtypes of non-small cell lung cancer (NSCLC)
include adenocarcinomas (37.5%), squamous and transitional cell carcinomas (19.8%), large cell
carcinomas (3.3%), and other tumor subtypes (24.5%). Patients diagnosed with localized, early stage
lung cancer have a 5-year survival rate of 49.5% and may be cured by surgical resection [4,5].
However, 77% of lung cancer patients have advanced stage disease at diagnosis, and their 5-year
survival rate is only 20.6% for disease that has spread to the regional lymph nodes or 2.8% for disease
that has metastasized to distant anatomical sites. Because patients who are diagnosed with early stage
lung cancer have a significantly better prognosis, screening (i.e., early detection) represents a practical
public health approach for decreasing lung cancer mortality.
Throughout the 1960s and 1970s, chest x-ray (CXR) alone or in conjunction with sputum cytology
were evaluated to detect early stage lung cancer [4,5]. To assess the feasibility, validity, and efficacy
of CXR for lung cancer screening, the NCI sponsored the Prostate, Lung, Colorectal, and Ovarian
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(PLCO) randomized screening trial, which was designed with a “no-screening” study arm and 89%
power to detect a 10% reduction in lung cancer mortality [6,7]. While awaiting PLCO trial results [8,9],
contemporary researchers have focused on developing low dose computed tomography and biomarkers
as potential lung cancer screening modalities [10–16].
The human epidermal growth factor receptor 2 (HER2/ERBB2/neu) proto-oncogene encodes a cell
surface receptor tyrosine kinase (RTK) that functions to regulate cell proliferation and survival [17].
HER2 amplification and protein overexpression have been implicated in the etiology and pathogenesis
of several human malignancies including lung cancer [18]. HER2 is overexpressed in 10–20% of
NSCLC cases and in perhaps as many as 30% of lung adenocarcinomas [19–23], where overexpression
is associated with adverse tumor characteristics and poor patient prognosis [24,25]. In addition to
full-length HER2, cells synthesize “soluble” HER2 (sHER2) isoforms [26–30]. These sHER2 isoforms
are produced either by alternate mRNA splicing or by proteolytic cleavage, and, are either secreted or
proteolytically shed from the plasma membrane into extracellular body fluids. Alternate splicing
results in mRNA transcripts that encode 68-kDa [30] and 100-kDa [28] sHER2 isoforms; whereas,
proteolytic cleavage results in 105-kDa [26] and 110-kDa [27] shed isoforms of sHER2 that
encompass only extracellular subdomains of this RTK. While it is widely assumed that the 105-kDa
sHER2 isoform represents the major constituent of human blood, a careful biochemical characterization
of serum sHER2 isoforms has not yet been performed. Nonetheless, multiple assays to quantify sHER2
have been developed and used to assess the potential clinical utility of serum sHER2 in cancer patients
across disease sites [31,32]. In particular, serum sHER2 has been examined in preliminary studies of
lung cancer, but has not yet been rigorously validated as a potential risk assessment, screening, and/or
diagnostic biomarker. Initial reports suggest that serum sHER2 is elevated in 5–64% of lung cancer
cases [23,32–36] and may be elevated many months prior to clinical diagnosis [33].
In this study, we evaluated 244 primary NSCLC cases and 218 healthy controls using an unmatched,
retrospective, case-control study design to determine whether age and/or gender are confounders or
effect modifiers of the relationship between sHER2 and NSCLC. We observed that sHER2
concentrations are associated with age among healthy men, and differ between healthy men and
women. Although sHER2 concentrations do not differ between healthy controls and patients with
NSCLC overall, they are slightly higher in patients with adenocarcinoma regardless of gender, but not
squamous cell carcinoma. Logistic regression models further demonstrate that sHER2 is a weak,
independent classifier of adenocarcinoma but not of squamous cell carcinoma, and when adjusted for
age and gender, the risk of adenocarcinoma increases with higher sHER2 concentrations. Moreover,
when mutually adjusted for each other, sHER2, age, and gender distinguish healthy controls from
patients with adenocarcinoma with 85.9% accuracy. These data suggest that albeit serum sHER2 is not
a strong, stand-alone discriminatory classifier of adenocarcinoma, its independence of age and gender
may confer some limited utility to sHER2 as a covariate in multivariate models for the risk assessment,
screening, and/or diagnosis of lung adenocarcinoma.
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2. Materials and Methods
2.1. Serum Samples
Serum samples were collected at the Mayo Clinic, Olmsted County, Rochester, MN, and stored
at −80 °C, as described in detail previously, from 218 healthy controls between 1981 to 1984, and
244 primary NSCLC cases between 1997 to 2002 through a “Normal Values Study” [37] and
“Comprehensive Lung Cancer Resource” [38], respectively; both protocols were approved by the
Mayo Clinic Institutional Review Board. Written informed consent was obtained from each participant
and all biospecimens were redacted of the patient’s identity. Each control was annotated with age and,
if female, menopausal status at venipuncture; and each lung cancer case was annotated with age, tumor
histological subtype, and, if female, menopausal status at diagnosis. Information concerning disease
stage and tumor grade were unavailable. The cases included 79 patients with squamous cell carcinoma
(SCC) and 165 with adenocarcinoma.
2.2. sHER2 ELISA
Serum sHER2 concentrations were measured using the sp185HER-2 ELISA (Bender MedSystems
Diagnostics GmbH, Vienna, Austria) according to the manufacturer’s instructions. The manufacturer
reports an analytical detection limit of 0.06 ng/mL sHER2 (two standard deviations above the mean
absorbance observed with sample buffer), mean intra-assay coefficient of variation of 1.9%, mean
inter-assay coefficient of variation of 5.8%, and mean spike recovery of 89% with serum for this
ELISA. In addition, the manufacturer reports no significant loss of serum sHER2 immunoreactivity
after five freeze-thaw cycles at −20 °C or following a 24 h storage period at −20 °C, 2–8 °C, 24 °C, or
37 °C, indicating that sHER2 is not an inherently unstable serum protein.
All serum samples in the present study were initially quantified in quadruplicate at a 1:20 dilution.
Serum samples yielding absorbance values outside the linear range of the assay’s standard curve,
below the biological detection limit (four standard deviations above the mean absorbance observed
with sample buffer), or with a coefficient of variation ≥20% were re-assayed at either a 1:10, 1:40,
1:80, or 1:120 dilution to obtain accurate estimates of serum sHER2 concentrations. We report a mean
inter-assay analytical detection limit of 0.02 ng/mL, mean inter-assay biological detection limit of
0.05 ng/mL, mean intra-assay coefficient of variation of 8.27% and 8.45% with normal serum sample
controls estimated to contain 3.2 and 7.7 ng/ml sHER2, respectively, and mean inter-assay coefficient
of variation of 4.11% and 2.26% with low and high quality control standards supplied by the
manufacturer estimated to contain 20.9 and 146.6 ng/ml sHER2, respectively.
2.3. Statistical Analysis
Statistical analyses were performed using “R” (R Foundation for Statistical Computing, Vienna,
Austria. http://www.R-project.org) and SAS version 9.2 (SAS Institute, Cary, NC, USA). Descriptive
statistics were calculated, and the nonparametric Wilcoxon rank-sum test was used to determine
whether sHER2 concentrations differ significantly between healthy controls and patients with primary
NSCLC, before and after stratification by gender, tumor histology, and menopausal status.
Nonparametric local weighted regression and Spearman’s rank-order correlation coefficients (ρ) were
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calculated to determine whether associations exist between sHER2 concentrations and age for healthy
controls or patients with NSCLC by gender. Univariate and multivariate logistic regression analyses
were performed to assess whether log-transformed sHER2 concentrations, age, and gender are
associated with lung cancer. Logistic regression models were compared for their ability to discriminate
NSCLC from control patients and adenocarcinoma from SCC tumors using the area under the curve
(AUC) of receiver operating characteristic (ROC) plots, and to assess the age- and gender-adjusted
effect of sHER2 on cancer risk. Statistical adjustment for multiple comparisons was performed with
the step-up procedure developed by Benjamini and Hockberg (1995) to control the false discovery rate
(FDR) [39,40]. FDR p-values <0.05 differ significantly between diagnostic groups; however, because
this is an exploratory hypothesis generating study of a small sample size, after stratification by gender
and tumor histological subtype, FDR p-values between 0.10 and 0.05 were considered to be of
borderline significance.
3. Results
3.1. sHER2 Concentrations Are Associated with Age in Healthy Men
This unmatched, retrospective, case-control study consists of 218 healthy controls (81 men,
137 women) and 244 patients with primary NSCLC (139 men, 105 women). The healthy men and
women in this study are younger (median age: 47 and 38 years, respectively) than the men and women
with NSCLC (median age: 68 and 64 years, respectively, p < 0.0001; FDR p < 0.0005, Table 1). Since
the cases and controls are unbalanced with regard to both gender and age, these parameters represent
potential confounders or effect modifiers of the association between serum sHER2 concentrations and
a classification of NSCLC. Therefore, we assessed whether sHER2 is associated with age among healthy
participants or patients with NSCLC in this study population by gender (Figure 1). These analyses
show that sHER2 concentrations are not associated with age among healthy women (Figure 1(B);
ρ = 0.055; p = 0.515; FDR p = 0.649), women with NSCLC (Figure 1(D); ρ = −0.082; p = 0.405; FDR
p = 0.537), or men with NSCLC (Figure 1(C); ρ = −0.110; p = 0.197; FDR p = 0.298). In contrast,
sHER2 concentrations decrease with age in healthy men (Figure 1(A); ρ = −0.354; p = 0.001; FDR
p = 0.004). Furthermore, sHER2 concentrations do not differ between healthy premenopausal vs.
postmenopausal women (p = 0.731; FDR p = 0.824), or between healthy premenopausal (p = 0.966;
FDR p = 0.966) and postmenopausal (p = 0.102; FDR p = 0.169) women vs. women with NSCLC of
the same menopausal status (Table 1). Stratification of NSCLC cases by histological subtype further
shows that sHER2 concentrations are not associated with age among all patients with SCC (ρ = −0.045;
p = 0.692; FDR p = 0.815) or adenocarcinoma (ρ = −0.063; p = 0.421; FDR p = 0.544), men with SCC
(ρ = −0.095; p = 0.530; FDR p = 0.653) or adenocarcinoma (ρ = −0.113; p = 0.281; FDR p = 0.414), and
women with SCC (ρ = −0.008; p = 0.963; FDR p = 0.966) or adenocarcinoma (ρ = −0.042; p = 0.726;
FDR p = 0.824).
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Table 1. Comparison of age and serum concentrations of soluble human epidermal growth
factor receptor 2 (sHER2) in healthy controls vs. lung cancer cases. Age and serum sHER2
concentrations are compared between healthy men and women (i.e., controls) vs. patients
with lung cancer by gender, and by menopausal status among healthy women.
Patient Groups

Median Age
(Range) in years

Wilcoxon/FDR P values

Healthy Men & Women (n = 218)
Lung Cancer Patients (n = 244)

43 (21–79)
66 (35– 88)

<0.0001/<0.0005

Healthy Men (n = 81)
Men with Lung Cancer (n = 139)

38 (24–79)
68 (35–88)

<0.0001/<0.0005

Healthy Women (n = 137)
Women with Lung Cancer (n = 105)

47 (21–76)
64 (36–83)

<0.0001/<0.0005

33 (21–57)
42 (33–62)

0.003/0.009

59 (45–76)
66 (42–83)

<0.0001/<0.0005

Healthy Premenopausal Women (n = 79)
Premenopausal Women with Lung Cancer
(n=11)
Healthy Postmenopausal Women (n = 56)
Postmenopausal Women with Lung Cancer
(n=90)
Patient Groups

Median sHER2
(Range) in ng/mL
2.91 (0.94– 68.60)
3.06 (1.15–138.63)

0.172/0.276

Healthy Men (n = 81)
Men with Lung Cancer (n = 139)

3.09 (1.18–68.60)
3.04 (1.15– 77.03)

0.573/0.690

Healthy Women (n = 137)
Women with Lung Cancer (n = 105)

2.71 (0.94–5.80)
3.07 (1.33–138.63)

0.052/0.098

2.82 (0.94–16.44)
2.74 (1.33–4.76)

0.966/0.966

2.61 (1.11– 18.01)
3.13 (1.43–38.63)

0.102/0.169

Postmenopausal Women with Lung Cancer
(n=90)

0.038/0.078

Wilcoxon/FDR P values

Healthy Men & Women (n = 218)
Lung Cancer Patients (n = 244)

Healthy Premenopausal Women (n = 79)
Premenopausal Women with Lung Cancer
(n=11)
Healthy Postmenopausal Women (n = 56)

0.061/0.112

0.022/0.051
0.958/0.966

0.731/0.824
0.324/0.440

Figure 1. Log soluble human epidermal growth factor receptor 2 (sHER2) concentrations
vs. age. Log-transformed serum sHER2 concentrations are plotted against age (years) with
nonparametric regression curves for healthy men (a), men with non-small cell lung cancer
(b), healthy women (c), and women with non-small cell lung cancer (d). Spearman
correlations (rho) and p-values are given for each comparison.
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3.2. sHER2 Concentrations are Higher in Patients with Adenocarcinoma
Although sHER2 concentrations do not differ between healthy controls vs. patients with NCSLC
(Table 1; p = 0.172; FDR p = 0.276), men vs. women with NSCLC (p = 0.958; FDR p = 0.966), or
healthy men vs. men with NSCLC (Figure 2(A); p = 0.573; FDR p = 0.690) in univariate analyses, they
are slightly higher in healthy men than healthy women (p = 0.022; FDR p = 0.051). In addition, sHER2
concentrations trend towards being higher in women with NSCLC compared to healthy women
(Figure 2(B); p = 0.052; FDR p = 0.098).
Figure 2. Scattergrams of sHER2 concentrations in healthy controls and patients with lung
cancer. Serum sHER2 concentrations are compared between healthy men vs. men with
non-small cell lung cancer (a), healthy women vs. women with non-small cell lung cancer
(b), men with squamous cell carcinoma (SCC) vs. adenocarcinoma (c), and women with
SCC vs. adenocarcinoma (d). Each data point represents the median sHER2 concentration
for one serum sample assayed in quadruplicate. The horizontal lines indicate the median
serum sHER2 concentration for each group of participants. Horizontal lines in the box plot
represent the first, second (median), and third quartiles; whiskers extend from the box to a
distance of 1.5 interquartile ranges.
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Table 2. Serum sHER2 concentrations by tumor histology. Serum sHER2 concentrations
are compared between lung cancer cases with squamous cell carcinomas vs. adenocarcinomas
by gender, and healthy men and women (i.e., controls) vs. patients with squamous cell
carcinomas and adenocarcinomas by gender.
Median sHER2
(Range) in ng/mL

Patient Groups

Wilcoxon/FDR
P values

Men & Women with Squamous Cell Carcinoma (n = 79)
Men & Women with Adenocarcinoma (n = 165)

2.57 (1.15–40.01)
3.21 (1.33–138.63)

0.004/0.012

Men with Squamous Cell Carcinoma (n = 46)
Men with Adenocarcinoma (n = 93)

2.63 (1.15–40.01)
3.21 (1.62–77.03)

0.035/0.074

Women with Squamous Cell Carcinoma (n = 33)
Women with Adenocarcinoma (n = 72)

2.51 (1.43–9.41)
3.21 (1.33–138.63)

0.044/0.086

Healthy Men & Women (n = 218)
Men & Women with Squamous Cell Carcinoma (n = 79)

2.91 (0.94–68.60)
2.57 (1.15–40.01)

0.302/0.421

Healthy Men & Women (n = 218)
Men & Women with Adenocarcinoma (n = 165)

2.91 (0.94– 68.60)
3.21 (1.33–138.63)

0.014/0.035

Healthy Men (n = 81)
Men with Squamous Cell Carcinoma (n = 46)
Men with Adenocarcinoma (n = 93)

3.09 (1.18–68.60)
2.63 (1.15–40.01)
3.21 (1.62–77.03)

Healthy Women (n = 137)
Women with Squamous Cell Carcinoma (n = 33)
Women with Adenocarcinoma (n = 72)

2.71 (0.94–35.80)
2.51 (1.43–9.41)
3.21 (1.33–138.63)

0.084/0.144

0.838/0.906

0.794/0.877

0.008/0.022

Table 3. Unadjusted relative risk of tumor histological subtype associated with serum
sHER2 concentration. Unadjusted odds ratios (OR) and 95% confidence intervals (95%
CI) comparing adenocarcinomas vs. squamous cell carcinomas are shown for quintiles of
serum sHER2 concentration by gender.
Quintiles of Serum sHER2
Concentration
≤1.85 ng/mL
2.40 ng/mL
3.00 ng/mL
3.65 ng/mL
≥6.60 ng/mL

OR (95% CI) for Women

OR (95% CI) for Men

referent
1.48 (1.09, 2.02)
2.06 (1.16, 3.66)
2.77 (1.23, 6.22)
6.74 (1.48, 30.67)

1.01 (0.57, 1.78)
1.49 (0.79, 2.82)
2.08 (0.94, 4.62)
2.79 (1.05, 7.74)
6.78 (1.36, 33.79)
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Further comparison of NSCLC cases by histological subtype shows that serum sHER2 concentrations
are slightly higher in patients with adenocarcinoma than SCC among men (Figure 2(C); Table 2;
p = 0.035; borderline significance, FDR p = 0.074), among women (Figure 2(D); p = 0.044; borderline
significance, FDR p = 0.086), and both genders combined (p = 0.004; FDR p = 0.012). Although
sHER2 concentrations do not differ between healthy controls and patients with SCC among men
(borderline significance, p = 0.084; FDR p = 0.144) or among women (p = 0.838; FDR p = 0.906),
sHER2 concentrations are higher in women (p = 0.008; FDR p = 0.022) but not in men with
adenocarcinoma (p = 0.794; FDR p = 0.877) compared to healthy controls of the same gender. Logistic
regression models and ROC curves (Figure 3) demonstrate that unadjusted for age, log-transformed
sHER2 concentrations have a statistically significant, but weak ability to differentiate patients with
adenocarcinoma from SCC among men (AUC = 0.610) and women (AUC = 0.623). Furthermore, both
men and women with high serum sHER2 concentrations have higher risk of having adenocarcinoma
than SCC (Table 3).
Figure 3. Receiver operating characteristic curves for log serum sHER2 concentrations of
adenocarcinoma vs. squamous cell carcinoma. ROC curves for log-transformed sHER2
concentrations are shown comparing patients with adenocarcinoma vs. SCC for men (blue
ROC curve labeled M) and women (red ROC curve labeled W), respectively.

3.3. sHER2 is a Weak, Independent Discriminatory Biomarker of Adenocarcinoma
Univariate logistic regression models show that both age (p < 0.0001; FDR p < 0.0005) and gender
(p < 0.0001; FDR p < 0.0005), but not log-transformed sHER2 concentrations (p = 0.191; FDR
p = 0.298) are associated with NSCLC when adenocarcinoma and SCC are combined (Table 4).
Likewise, age (p < 0.0001; FDR p < 0.0005) and gender (p = 0.002; FDR p = 0.007), but not sHER2
concentrations (p = 0.290; FDR p = 0.415) are associated with SCC. In contrast, sHER2 concentrations
(p = 0.026; borderline significance, FDR p = 0.057), age (p < 0.0001; FDR p < 0.0005), and gender
(p = 0.0003; FDR p = 0.0012) are associated with adenocarcinoma. Multivariate logistic regression
models further demonstrate that log-transformed sHER2 remains independently associated with
adenocarcinoma (p = 0.022; FDR p = 0.051), but not SCC (p = 0.891; FDR p = 0.945) or all NSCLC

Diagnostics 2013, 3

22

tumors combined (borderline significance, p = 0.082; FDR p = 0.144) when adjusted for age and
gender. ROC curves derived from univariate logistic regression models illustrate that age is a strong
discriminator of healthy controls from all NSCLC tumors combined (AUC = 0.858), as well as cases
diagnosed with SCC (AUC = 0.895) or adenocarcinoma (AUC = 0.840), potentially reflecting
ascertainment bias; while gender is a weak discriminator of all NSCLC tumors combined
(AUC = 0.594), SCC (AUC = 0.601) or adenocarcinoma (AUC = 0.591) (Table 4 and Figure 4).
In contrast, log-transformed sHER2 alone does not discriminate healthy controls from all NSCLC
cases combined (AUC = 0.537) or SCC (AUC = 0.539), but weakly discriminates adenocarcinoma
(AUC = 0.573). When mutually adjusted for each other, sHER2, age, and gender yield 85.9% accuracy
(AUC) to discern healthy controls from patients with lung adenocarcinoma across all cut-off
thresholds of sHER2 (Table 4). Notably, the ability to discern healthy controls from patients with
adenocarcinoma is contributed mainly by age rather than sHER2 or gender (AUC = 0.840 with age
alone vs. AUC = 0.859 with age, gender, and sHER2 combined). These ROC curves further
demonstrate that gender is an important confounder of age for discerning healthy controls from
patients with adenocarcinoma, but not SCC (compare Figure 4(F) to 4(E) and 4(I) to 4(H)), whereby
being male is a stronger determinant of adenocarcinoma than being female. For example, ROC curves
that include age and sHER2 (or age alone, Figure 4(F)) show statistically significantly better
discrimination of healthy controls vs. patients with adenocarcinoma among men (AUC = 0.91) than
among women (AUC = 0.78) (Figure 4(I)); notably, the sensitivity to detect adenocarcinoma is 60%
for men, but only 30% for women at 95% specificity (Figure 4(I)). Adjusted for age and gender, the
risk of adenocarcinoma increase with higher serum sHER2 concentrations (Table 5). For example,
adjusted for age, the odds of adenocarcinoma are 3.95 (95% CI: 1.22, 12.81) among women and 7.93
(95% CI: 2.26, 27.82) among men at a value of >6.60 ng/mL sHER2 compared to the referent value of
<1.85 ng/mL. The confounding effect of gender on age is not observed in logistic regression models
that include age and sHER2 (or age alone) for patients with SCC (Figure 4(E)); i.e., men (AUC = 0.91)
and women (AUC = 0.91) with SCC are discriminated equally well from healthy controls of the same
gender by age alone (Figure 4(H)). Finally, no evidence of effect modification by age or gender on the
association between serum sHER2 and NSCLS, adenocarcinoma, or SCC is observed in this dataset
(not shown). Taken together, these analyses show that age and gender are classifiers of NSCLC, SCC,
and adenocarcinoma; as well as confounders of the association between sHER2 and adenocarcinoma
in this dataset. Nevertheless, serum sHER2 remains a weak, statistically significant, independent
discriminatory biomarker of lung adenocarcinoma, but not of SCC, after adjusting for age and gender.
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Table 4. Logistic regression models of non-small cell lung cancer (NSCLC) with age,
gender, and log-transformed serum sHER2 concentrations as covariates. Univariate and
multivariate logistic regression models are shown of men and women with lung cancer
compared to healthy men and women (i.e., controls) for all lung cancer cases combined, and
stratified by tumor histological subtype.
Univariate Logistic Regression Models
Maximum
Likelihood
Estimate

Standard
Error

0.106
−0.766
0.429

0.010
0.187
0.328

125.216
16.728
1.711

<0.0001/<0.0005
<0.0001/<0.0005
0.191/0.298

0.858
0.594
0.537

Squamous Cell Carcinomas vs. Controls
Age
0.129
Gender
−0.818
Log sHER2
−0.565

0.016
0.265
0.534

66.308
9.499
1.119

<0.0001/<0.0005
0.002/0.007
0.290/0.415

0.895
0.601
0.539

Adenocarcinomas vs. Controls
Age
Gender
Log sHER2

0.010
0.207
0.350

95.433
12.788
4.937

<0.0001/<0.0005
0.0003/0.0012
0.026/0.057

0.840
0.591
0.573

Patient Groups
Parameters
All Lung Cancer Cases vs. Controls
Age
Gender
Log sHER2

0.098
−0.741
0.777

Wald Χ2

Χ2/FDR
P value

AUC

Multivariate Logistic Regression Models
Maximum
Likelihood
Estimate

Standard
Error

0.112
−0.831
0.801

0.010
0.252
0.461

121.132
10.831
3.024

<0.0001/<0.0005
0.001/0.004
0.082/0.144

0.877

Squamous Cell Carcinomas vs. Controls
Age
0.140
Gender
−1.416
Log sHER2
0.112

0.018
0.386
0.817

63.664
13.462
0.019

<0.0001/<0.0005
0.0002/0.0009
0.891/0.945

0.917

Adenocarcinomas vs. Controls
Age
Gender
Log sHER2

0.011
0.267
0.472

93.161
6.807
5.235

<0.0001/<0.0005
0.009/0.024
0.022/0.051

0.859

Patient Groups
Parameters
All Lung Cancer Cases vs. Controls
Age
Gender
Log sHER2

0.102
−0.697
1.080

Wald Χ2

Χ2/FDR
P value

AUC

Table 5. Age-adjusted relative risk of adenocarcinoma associated with serum sHER2
concentration. Age-adjusted odds ratios (OR) and 95% confidence intervals (95% CI)
comparing healthy men and women (i.e., controls) vs. patients with adenocarcinoma are
shown for quintiles of serum sHER2 concentration by gender.
Quintiles of Serum sHER2

OR (95% CI) for Women

OR (95% CI) for Men

Concentration
≤1.85 ng/mL
2.40 ng/mL
3.00 ng/mL
3.65 ng/mL
≥6.60 ng/mL

referent
1.32 (1.04, 1.68)
1.69 (1.08, 2.64)
2.08 (1.11, 3.90)
3.95 (1.22, 12.81)

2.01 (1.19, 3.39)
2.66 (1.52, 4.66)
3.38 (1.74, 6.57)
4.18 (1.90, 9.21)
7.93 (2.26, 27.82)
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Figure 4. Receiver operating characteristic curves of lung cancer cases vs. controls. ROC
curves are shown comparing all cancer cases vs. healthy controls (a, d, g), SCC vs. healthy
controls (b, e, h), and adenocarcinoma vs. healthy controls (c, f, i). ROC curves are shown
for a reduced model of log-transformed sHER2 concentrations alone (a, b, c), a model of
age alone (d, e, f), and a model including both age and log-transformed sHER2
concentrations (g, h, i) for both men and women combined (black ROC curves labeled C),
men only (blue ROC curves labeled M), and women only (red ROC curves labeled W).

4. Discussion
Steroid hormones have been implicated in the regulation of HER2 expression; however, the age and
gender specific effects of steroids on HER2 expression, as well as on sHER2 shedding is not completely
understood. In human breast cancer cells in vitro, estradiol is a potent inhibitor of HER2 expression
and sHER2 shedding [41–44]; whereas, progesterone positively regulates HER2 expression [45].
In contrast, neither estrogen nor progesterone regulates HER2 expression in ovarian cancer cells [46].
Among men with prostate cancer, high HER2 expression has been associated with androgen
ablation therapy and androgen independent prostate carcinoma [47]. Among healthy women, oral
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contraceptive use and hormone replacement therapy have been associated with lower serum sHER2
concentrations [48]. In pregnant women, serum sHER2 concentrations are lower during the first and
second trimester in pregnant women, which is when estrogen concentrations increase, but are higher
during the third trimester [49–51]. Finally, elevated serum sHER2 concentrations among women with
preeclampsia vs. a normal pregnancy suggest the possibility of fetomaternal transfer during the third
trimester of pregnancy [49,52]. Together, these observations suggest that steroid hormones may
regulate both the biosynthesis and shedding of sHER2 into circulatory fluids. Our observations that
sHER2 concentrations decrease with age in healthy men, and that age and gender confound the
relationship between sHER2 concentrations and lung adenocarcinoma are consistent with hormonal
regulation of HER2 expression and/or shedding. These observations underscore the importance of
adjusting for age, gender, and other potential confounding variables that may affect steroid hormone
biosynthesis, such as body mass and smoking [53,54], when evaluating the utility of sHER2 for the
risk assessment, early detection, and diagnosis of adenocarcinoma using epidemiological study designs
and multivariate statistical methods.
Limitations and caveats of this retrospective study include: (a) an inability to assess the effect of
long term storage at −80 °C on serum sHER2 stability, (b) an inability to assess potential differences in
serum sHER2 concentrations between non-small cell adenocarcinomas compared to large or small cell
carcinomas; (c) an inability to assess potential differences in serum sHER2 concentrations by disease
stage or tumor grade; (d) lack of data on potential confounders or effect modifiers of sHER2
concentrations such as smoking status, body mass, personal and family cancer history, carcinogen
exposure, menstrual cycle phase, parity, and exogenous hormone use among women; (e) potential
ascertainment and cohort bias of the control group, which was not selected using the same enrollment
criteria (e.g., age and smoking status) or at random during the same time period from the source
population as the cases; and (f) an inability to assess the risk of developing lung adenocarcinoma
among asymptomatic individuals with pre-diagnostic serum samples. Given these caveats and
limitations, it will be important to conduct well-designed transitional studies to assess the effects of
storage at −80 °C on serum sHER2 concentrations, and prospective case-control studies to further
validate sHER2 as a weak, independent biomarker of lung adenocarcinoma using multivariate models.
Such studies should include incident cases of lung adenocarcinoma, other malignant and benign lung
neoplasms, and healthy controls selected randomly from the study population.
Several reports indicate that serum sHER2 concentrations have 5–64% sensitivity to detect lung
cancer of various histological subtypes using cut-off thresholds that correctly classify healthy controls
with 95% specificity [23,32–36]. Sensitivity was reported to be higher for patients with late stage lung
cancer and for patients with adenocarcinoma compared to SCC, large cell carcinoma, and small cell
carcinoma [23,32,34,35]. In general, these studies were small, used disparate immunoassays, or used
previously established cut-off thresholds from an external control study group [23]. Additionally, most
of these studies did not control for confounding by age, gender, and other variables such as smoking
by using a matched, case-control study design or by adjusting for confounding in an unmatched,
case-control study design with multivariate logistic regression methods [23,32,34–36]. Notably, the
highest reported sensitivity (64%) and specificity (95%) of sHER2 concentrations to discern healthy
controls from lung cancer cases was reported for a small age-, gender-, ethnic group-, and
smoking-matched case-control study [33]. That age might be a potential confounder or effect modifier
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of the association between sHER2 and cancer is supported by our observation that sHER2
concentrations decrease with age in healthy men, and by a previous report showing that sHER2
concentrations increase with age in healthy women independently of menopausal status [55]. Here, it is
observed that sHER2 concentrations are higher in primary NSCLC patients with adenocarcinoma than
SCC, thus confirming that biological differences exist between these histological subtypes. Moreover,
we report that the ability of sHER2 concentrations to discern healthy controls from patients with
adenocarcinoma, but not SCC, is indeed confounded by age and gender in our dataset (Table 4 and
Figure 4). When mutually adjusted for each other, sHER2, age, and gender yield 85.9% accuracy to
classify controls from primary adenocarcinoma patients (Table 4). However, the strength to discern
healthy controls from patients with adenocarcinoma is contributed mainly by age, not sHER2 and
gender (AUC = 0.840 with age alone vs. AUC = 0.859 with age, gender, and sHER2 combined).
The accuracy to discern adenocarcinoma patients from controls with age-adjusted sHER2 concentrations
is 91% among men, but only 78% among women (Figure 4(I)), suggesting that additional confounders
may be influencing the association between sHER2 and adenocarcinoma among women. Notably, at
95% specificity, the sensitivity to detect adenocarcinoma is 60% for men and 30% for women; these
statistics are similar to those reported by Brandt-Rauf and colleagues, who used a matched case-control
study design to control for confounding by age, gender, ethnicity, and smoking [33]. Importantly, the
data reported here show that sHER2 is a weak, but statistically significant, independent classifier of
adenocarcinoma. Although sHER2 is not a strong, stand-alone classifier of adenocarcinoma, its
independence of age and gender may make sHER2 a useful covariate (with age, gender, and other
biomarkers) in multivariate screening and diagnostic models of lung adenocarcinoma.
Risk prediction models that include smoking are useful for advising patients about their propensity
to develop lung cancer. However, while smoking is a well-known risk factor for lung cancer,
considered alone, smoking history has limited ability to predict which smokers will develop lung
cancer. Other contributing epidemiological, clinical, and biological (i.e., biomarkers) factors may
improve lung cancer risk prediction among smokers and even non-smokers [56,57]. Several groups
have developed lung cancer risk models using the variables of age, smoking history, carcinogen
exposure, and family history [58–64]. However, few of these studies included serum biomarkers,
despite our understanding that biomarkers represent promising risk assessment tools [56,57,59,64].
Recently, Spitz and colleagues modestly improved their risk model, which included environmental
tobacco smoke, family cancer history, dust exposure, prior respiratory disease, hay fever, and smoking
history variables by adding two in vitro markers of DNA repair capacity (host-cell reactivation and
mutagen sensitivity) [65]. Adding these markers significantly improved the model’s accuracy to
discriminate between lung cancer cases and controls from 67% to 70% among former smokers
(p = 0.006), and from 68% to 73% among current smokers (p = 0.0048). Similarly, Prindiville and
colleagues found that sputum samples characterized by moderate to worse cytological atypia defined a
cohort of high-risk patients who were at increased risk of developing lung cancer [66]. Notably, we
observe that, adjusted for age, the relative risk (odds) of adenocarcinoma is 3.95 (95% CI: 1.22, 12.81)
among women and 7.93 (95% CI: 2.26, 27.82) among men with high sHER2 concentrations
(>6.60 ng/mL) compared to women or men with low sHER2 concentrations (<1.85 ng/mL; Table 5).
These data are consistent, but not conclusive, with a role for serum sHER2 as a biological marker of
risk for primary non-small cell lung adenocarcinoma.
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Cancer treatment is undergoing a paradigm shift from the use of broad-spectrum cytotoxic
chemotherapeutics to biologically targeted therapeutics [67], including HER-targeted drugs [68]. The
HER family of receptors, EGFR/HER1, HER2, HER3, and HER4 are rational targets for anti-cancer
drugs because they activate complex signal transduction pathways that lead to tumor cell proliferation,
survival, and metastasis [69]. In patients with NSCLC, EGFR-targeted RTK inhibitors, such as
gefitinib and erlotinib, have produced objective response rates in about 10% of patients with advanced
stage disease and modest improvements in patient survival [70–72]. Clinical trials with HER2-targeted
monoclonal antibodies, trastuzumab and pertuzumab, also have shown efficacy in some NSCLC
patients [70,73,74]; however, trials with trastuzumab have been insufficiently powered to determine
whether NSCLC patients with HER2 gene amplification or overexpression as determined by
immunohistochemistry may benefit from treatment [75,76]. Notably, responsiveness and efficacy
toward HER-targeted therapeutics is dependent on the selection of patients who present with the active
target of choice, and accurate methods to identify these patients [77,78]. Here, we observe that serum
sHER2 concentrations detected by ELISA are higher in a subset of primary NSCLC patients with
adenocarcinoma (adjusted for age, 60% of men and 30% of women had sHER2 concentrations above
the 95th cut-off threshold for healthy controls), suggesting that sHER2 may warrant investigation as a
theragnostic biomarker to select a subset of patients with lung adenocarcinoma for treatment with
HER2-targeted drugs.
5. Conclusions
In summary, we have observed that serum sHER2 concentrations are higher in a subset of patients
with primary adenocarcinoma compared to patients with SCC or healthy controls, and weakly, but
independently associated with adenocarcinoma even after adjusting for confounding by age and
gender. These results are consistent with the hypothesis that sHER2 may have some limited clinical
utility as a serum biomarker of non-small cell lung adenocarcinoma, if properly adjusted for
confounding by age, gender, and variables that affect circulating and tissue steroid hormone
concentrations (e.g., body mass, smoking, oral contraceptive use, and hormone replacement therapy)
or circulating steroid hormones themselves. We conclude that even though serum sHER2 is not a
strong, stand-alone discriminatory biomarker of adenocarcinoma, sHER2 may be a useful, independent
covariate in multivariate regression models that warrants further investigation for the risk assessment,
screening, and diagnosis of lung adenocarcinoma in well-designed epidemiological studies that control
for confounding by age, gender, and other demographical, epidemiological, behavioral, and
environmental variables using multivariate regression methods or a matched case-control study design.
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